Correspondence 0001493152-23-023970 from ZyVersa Therapeutics, Inc. (ZVSA)
ZyVersa Therapeutics, Inc.
Date: July 7, 2023 · CIK: 0001859007 · Accession: 0001493152-23-023970
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-272657
Letter
VIA EDGAR Securities and Exchange Commission ZyVersa Therapeutics, Inc. Registration Statement on Form S-1 Filed June 15, 2023 File No. 333-272657 (the “Registration Statement”)
Dear Mr. Gorsky:
ZyVersa Therapeutics, Inc., a Delaware corporation (the “Company”), is hereby responding to the comment from the staff (the “Staff”) of the Securities and Exchange Commission (the “Commission”) received orally on July 5, 2023, relating to the above-referenced Registration Statement. Where applicable, we make reference to the Company’s Amendment No. 2 to its Registration Statement on Form S-1 being filed with the Commission today (the “Amendment”).
Comment 1:
We note your response to our prior comment 1 and the disclosure added to the bottom of the cover page stating that the offering will terminate no later than the second business day after the date of the prospectus. Please further revise this disclosure to provide the actual date the offering will end as required by Item 501(b)(8)(iii) of Regulation S-K.
Response:
In response to the Staff’s comment, the Company has revised the cover page to disclose that the offering will end no later than July 31, 2023.
Please contact our counsel, Jack Hogoboom of Lowenstein Sandler LLP at (973) 597-2382, or the undersigned with any questions regarding the contents of this letter or the Amendment.
Sincerely,
/s/ Stephen C. Glover
Show Raw Text
CORRESP
1
filename1.htm
ZYVERSA THERAPEUTICS, INC.
2200 N. Commerce Parkway, Suite 208
Weston, FL 33326
(754) 231-1688
July 7, 2023
VIA EDGAR
Joshua Gorsky
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Re:
ZyVersa Therapeutics, Inc.
Registration Statement on Form S-1
Filed June 15, 2023
File No. 333-272657 (the “Registration Statement”)
Dear Mr. Gorsky:
ZyVersa Therapeutics, Inc., a Delaware corporation
(the “Company”), is hereby responding to the comment from the staff (the “Staff”)
of the Securities and Exchange Commission (the “Commission”) received orally on July 5, 2023, relating to the
above-referenced Registration Statement. Where applicable, we make reference to the Company’s Amendment No. 2 to its Registration
Statement on Form S-1 being filed with the Commission today (the “Amendment”).
Comment 1:
We note your response to our prior comment 1 and the
disclosure added to the bottom of the cover page stating that the offering will terminate no later than the second business day after
the date of the prospectus. Please further revise this disclosure to provide the actual date the offering will end as required by Item
501(b)(8)(iii) of Regulation S-K.
Response:
In response to the Staff’s comment, the Company
has revised the cover page to disclose that the offering will end no later than July 31, 2023.
Please contact our counsel, Jack Hogoboom of Lowenstein
Sandler LLP at (973) 597-2382, or the undersigned with any questions regarding the contents of this letter or the Amendment.
Sincerely,
/s/ Stephen C. Glover
Stephen C. Glover
Chairman, President and Chief Executive Officer
cc: John D. Hogoboom, Esq.